Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Five RNAi-Related Patent Applications: Jan 19, 2006

Premium

Title: Double-Stranded Oligonucleotides

Number: 20060009409

Filed: Feb. 2, 2005

Inventor: Todd Woolf, Ipifini

"Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed" in the patent application, its abstract states. "The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions."


Title: SiRNA-Mediated Gene Silencing with Viral Vectors

Number: 20060009408

Filed: Jan. 31, 2005

Lead Inventor: Beverly Davidson, University of Iowa (Sirna Therapeutics)

According to the patent application's abstract, the invention "is directed to viral vectors encoding small interfering RNA molecules targeted against a gene of interest, and methods of using these viral vectors."


Title: In Vivo Production of Small Interfering RNAs that Mediate Gene Silencing

Number: 20060009402

Filed: July 12, 2002

Lead Inventor: Phillip Zamore, University of Massachusetts

"The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference pathway," the patent application's abstract states. "By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells."


Title: Lipid-Encapsulated Interfering RNA

Number: 20060008910

Filed: June 7, 2005

Lead Inventor: Ian Mac Lachlan, Protiva Biotherapeutics

The invention, the patent application's abstract states, "provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations. "


Title: Control of Gene Expression via Light-Activated RNA Interference

Number: 20060008907

Filed: June 9, 2005

Lead Inventor: Simon Friedman, University of Missouri

"A method for controlling the spacing, timing and degree of gene expression that includes selecting a target mRNA, obtaining siRNA corresponding to the target mRNA, modifying the siRNA with a photo-labile group to inhibit RNA interference, introducing the modified siRNA into a cell, and selectively irradiating the cell with light having a predetermined wavelength," the patent application's abstract states. "A modified siRNA capable modulating gene expression that includes an siRNA that targets a predetermined complementary mRNA and at least one photo-labile group attached to said siRNA."

 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.